FDA Approves SUGAMMADEX — Somerset Therapeutics, LLC

Somerset Therapeutics has received FDA approval for the intravenous formulation of sugammadex, the antidote to rocuronium bromide, marking a pivotal expansion of its portfolio. This regulatory milestone intensifies market competition and represents a significant commercial opportunity by addressing the critical need for rapid reversal agents in medical settings.